The main objective of the study is to investigate if resveratrol supplementation can improve overall and muscle-specific insulin sensitivity in first-degree relatives of type 2 diabetic patients. As a secondary objective the investigators want to investigate whether the improved insulin sensitivity can be attributed to improved muscle mitochondrial oxidative capacity and a reduced intrahepatic and cardiac lipid content. Furthermore, in a subset of the participants the investigators want to investigate the effect of resveratrol on glucose uptake in brown adipose tissue.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
15
A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
Maastricht University Medical Centre
Maastricht, Limburg, Netherlands
insulin sensitivity: overall, muscle- and liver specific
Hyperinsulinemic euglycemic clamp combined with indirect calorimetry: Glucose infusion rate (GIR), rate of appearance and disappearance of glucose (Ra, Rd), endogenous glucose production (EGP), oxidative and non-oxidative glucose disposal, carbohydrate and lipid oxidation, energy expenditure.
Time frame: 30 days after supplementation
muscle mitochondrial oxidative capacity (in vivo and ex vivo)
In vivo: Phosphocreatine levels will be measured by P-MRS (before, during, and after exercise) as a marker for in vivo mitochondrial function in the vastus lateralis muscle. Ex vivo mitochondrial function in skeletal muscle will be measured by oxygen consumption in muscle fibres (muscle biopsy) on lipid-derived and carbohydrate-derived substrates.
Time frame: 30 days after supplementation
intramyocellular lipid content
Skeletal muscle lipid accumulation measured by immunohistochemistry in muscle biopsy from vastus lateralis muscle
Time frame: 30 days after supplementation
intrahepatic lipid content
Intrahepatic lipid content measured with H-MRS
Time frame: 30 days after supplementation
intracardiac lipid content
Intracardiac lipid content measured with H-MRS
Time frame: 30 days after supplementation
heart function
Cardiac function: diastolic and systolic heart function will be measured with ultrasound
Time frame: 30 days after supplementation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
brown adipose tissue activity
subjects will be exposed to an individualized cooling protocol, after which an 18F-FDG PET/CT scan is made
Time frame: 34 days after supplementation